Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-240
- Development stage
- Unknown
- Lead developer
- SCOHIA PHARMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SCO-240 is an orally bioavailable small molecule drug developed by SCOHIA PHARMA that acts as a selective antagonist of the somatostatin receptor type 5 (SSTR5). Currently in Phase 1 clinical development, the drug is primarily being investigated for growth hormone deficiency (GHD), including pediatric growth hormone deficiency (PGHD). By antagonizing SSTR5, SCO-240 stimulates the secretion of growth hormone (GH) from the pituitary gland. Clinical studies have demonstrated its ability to robustly increase GH levels in healthy individuals while maintaining a favorable safety and tolerability profile. Its pharmacokinetic properties support once-daily oral dosing. In addition to growth hormone disorders, SCO-240 is also being explored for potential applications in female infertility and alopecia.
02
Targets
Beyond the preview
Go deeper on SCO-240.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-240.